Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

导出原文传递

翻译打印收藏纠错

作者： Longo-Munoz, F. ^[1] ; Argiles, G. ^[2] ; Tabernero, J. ^[3] ; Cervantes, A. ^[4] ; Gravalos, C. ^[5] ; Pericay, C. ^[6] ; Gil-Calle, S. ^[7] ; Mizuguchi, H. ^[8] ; Carrato-Mena, A. ; Limon, M. L. ; Garcia-Carbonero, R.

作者单位： Taiho Oncol Inc, Carnegie Ctr 202, Suite 100, Princeton, NJ 08540 USA ^[1] Hosp Univ Ramon & Cajal, Serv Oncol Med, Carretera Colmenar Viejo Km 9-100, Madrid 28034, Spain ^[2] Hosp Univ Virgen del Rocio, Oncol Med S, Seville, Spain ^[3] Hosp Carlos Haya, Av Carlos Haya S-N, Malaga 29010, Spain ^[4] Univ Valencia, Biomed Res Inst INCLIVA, Av Menendez Pelayo 4 Accesorio, Valencia 46010, Spain ^[5] Hosp Univ Doce Octubre, Serv Oncol Med, Ave Cordoba Km 5-4, Madrid 28041, Spain ^[6] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, P Vall dHebron 119-129, Barcelona 08035, Spain ^[7] Hosp Univ Sabadell, Corp Sanitaria Parc Tauli, Parc Tauli 1, Sabadell 08208, Spain ^[8]

关键词 TAS-102 Metastatic colorectal cancer Trifluridine Tipiracil hydrochloride Fluoropyrimidine Spain

发布时间 2017-04-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交